Previous cancer | 610 | 38 | 6.2 | 35.8 | 216 (35.4) | 19 (50.0) | 127 (20.8) | 3 (7.9) | 267 (43.8) | 16 (42.1) |
|
Comorbidity | 651 | 21 | 3.2 | 19.8 | 170 (26.1) | 10 (47.6) | 346 (53.1) | 6 (28.6) | 135 (20.7) | 5 (23.8) |
|
First consultation | 2847 | 36 | 1.3 | 34.0 | 747 (26.2) | 22 (61.1) | 1840 (64.6) | 11 (30.6) | 260 (9.1) | 3 (8.3) |
|
Not first consultation | 2553 | 60 | 2.4 | 56.6 | 640 (25.1) | 33 (55.0) | 1458 (57.7) | 12 (20.0) | 455 (17.8) | 15 (25.0) |
|
Duration of symptoms, weeks | | | | | | | | | | |
0–1 | 535 | 8 | 1.5 | 7.5 | 113 (21.1) | 4 (50.0) | 366 (68.4) | 3 (37.5) | 55 (10.3) | 1 (12.5) |
2–7 | 1283 | 19 | 1.5 | 17.9 | 359 (28.0) | 16 (84.2) | 795 (62.0) | 3 (15.8) | 129 (10.1) | 0 (0) |
8–23 | 1320 | 25 | 1.9 | 23.6 | 426 (32.3) | 18 (72.0) | 775 (58.7) | 4 (16.0) | 116 (8.8) | 3 (12.0) |
24–51 | 491 | 10 | 2.0 | 9.4 | 140 (28.5) | 6 (60.0) | 288 (58.7) | 2 (20.0) | 61 (12.4) | 2 (20.0) |
≥52 | 785 | 13 | 1.7 | 12.3 | 148 (18.9) | 5 (38.5) | 524 (66.8) | 2 (15.4) | 107 (13.6) | 6 (46.2) |
|
Supplementary actions | | | | | | | | | | |
Laboratory tests | 2719 | 52 | 1.9 | 49.1 | 838 (30.8) | 33 (63.5) | 1569 (57.7) | 12 (23.1) | 312 (11.5) | 7 (13.5) |
Imaging | 1140 | 33 | 2.9 | 31.1 | 461 (40.4) | 20 (60.6) | 561 (49.2) | 7 (21.2) | 118 (10.4) | 6 (18.2) |
Referrals | 1342 | 41 | 3.1 | 38.7 | 555 (41.4) | 30 (73.2) | 614 (45.8) | 4 (9.8) | 173 (12.9) | 7 (17.1) |
0 action | 2370 | 24 | 1.0 | 22.6 | 249 (10.5) | 5 (20.8) | 1644 (69.4) | 8 (33.3) | 466 (19.7) | 11 (45.8) |
1 action | 2847 | 42 | 1.5 | 39.6 | 758 (26.6) | 25 (59.5) | 1729 (60.7) | 10 (23.8) | 353 (12.4) | 7 (16.7) |
2 actions | 958 | 36 | 3.8 | 34.0 | 428 (44.7) | 26 (72.2) | 428 (44.7) | 5 (13.9) | 97 (10.1) | 5 (13.9) |
3 actions | 146 | 4 | 2.7 | 3.84 | 80 (54.8) | 2 (50.0) | 53 (36.3) | 1 (25.0) | 12 (8.2) | 1 (25.0) |